Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001970214 | SCV002239746 | pathogenic | Neurofibromatosis, type 1 | 2020-11-11 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with NF1-related conditions. This sequence change creates a premature translational stop signal (p.Ile342Aspfs*12) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (ExAC no frequency). |
Ambry Genetics | RCV002370610 | SCV002685169 | pathogenic | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2020-01-22 | criteria provided, single submitter | clinical testing | The c.1023_1024insGACA pathogenic mutation, located in coding exon 9 of the NF1 gene, results from an insertion of 4 nucleotides at position 1023, causing a translational frameshift with a predicted alternate stop codon (p.I342Dfs*12). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |